Last reviewed · How we verify
zetomipzomib in open-label extension — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
zetomipzomib in open-label extension (zetomipzomib in open-label extension) — Kezar Life Sciences, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| zetomipzomib in open-label extension TARGET | zetomipzomib in open-label extension | Kezar Life Sciences, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- zetomipzomib in open-label extension CI watch — RSS
- zetomipzomib in open-label extension CI watch — Atom
- zetomipzomib in open-label extension CI watch — JSON
- zetomipzomib in open-label extension alone — RSS
Cite this brief
Drug Landscape (2026). zetomipzomib in open-label extension — Competitive Intelligence Brief. https://druglandscape.com/ci/zetomipzomib-in-open-label-extension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab